Delphinus Medical Technologies Secures $27.6M to Advance Revolutionary SoftVue Breast Imaging Technology

Delphinus Medical Technologies, Inc. is thrilled to announce an exciting funding milestone with a successful raise of $27.6 million, a pivotal achievement that will fuel its mission of advancing breast imaging innovation. Founded in 2010 as a spin-out of the renowned Karmanos Cancer Institute in Detroit, MI, Delphinus Medical Technologies has continually pushed the boundaries of diagnostic imaging. Headquartered in Novi, MI, the company is uniquely positioned as an innovation leader in advanced ultrasound development, having pioneered the first whole breast ultrasound system that harnesses the power of sound and water. This breakthrough technology, embodied in its flagship SoftVue™ system, utilizes proprietary TriAD™ (triple acoustic detection) technology, enabling the capture of reflection echoes from every direction around the breast, along with transmitted signals that pass through tissue. With the recent funding boost, Delphinus is set to accelerate its efforts in enhancing imaging techniques that empower medical professionals to better define and diagnose breast disease while elevating the overall patient experience. The funds will further support research and development, expand clinical studies, and enhance market access initiatives to reach more healthcare facilities and ultimately more patients. Already having earned 510(k) clearance from the U.S. Food and Drug Administration for diagnostic imaging purposes, SoftVue™ is revolutionizing the way breast imaging is approached—offering a radiation-free, comfortable alternative that opens new possibilities for women of all ages. This strategic infusion of capital underscores the investment community’s confidence in Delphinus’s approach to transforming breast imaging and marks a significant step towards broader adoption and improved patient outcomes nationwide.